Table 1.
Synopsis of data from previous reviews on severe CMV infections and in immunocompetent patients.
| Reference Year of publication | Number of patients | Site involved | Patient demographics | Comorbidity | Antiviral treatment | Outcome |
| [2]/2007 | 11 | Portal vein thrombosis | 55% M/MA 34 y and one infant 4 m | Known thromboembolic risk factors in 64% | ND | Complete thrombus resolution in 73% of patients 2/11 received antiviral treatment |
| [3]/2005 | 44 | Colitis | 61.5% M/61.1(25–71) | 18 IM (8 with renal failure, 6 with DM, 2 pregnant), 18 with NM and 10 NC | 18.8% in the IM 44% in the NM group 40% in the NC group |
MR and SR: 56.3% and 18.8% in the IM, 22% and 33% in the NM group, 10% and 50% in the NC group |
| [4]/2003 | 4 | Vascular thrombosis and pulmonary embolism | 40% M/29–38 y and one neonate | One patient APA, and another FVLH | Ganciclovir one patient, none another ND for 3 patients | Good for personal 2 patients (1 of them received treatment) ND for 3 |
| [5]/2001 | 15 | Colitis | MA 63+/-20 y | ND | 34% received AT | 31% in the AT group died 36% of those that did not receive AT died** |
| [6]/2000 | 19 | Meningoencephalitis [16 monophasic (2 of them had multiorgan involvement)] and 3 paroxysmal] | 17–78 y | ND | 12/16 with monophasic received treatment (8 acyclovir, 3 ganciclovir,1 adenine-arabinoside) None with paroxysmal received treatment |
Monophasic without treatment: 4/5 had CR while 1/5 PR With treatment: 13/16 CR, 1/16 PR, 2/16 deaths Paroxysmal: All CR |
| [7]/1997 | 27 | Hepatitis (15), Nervous system (9), Pneumonitis (2), colitis (1) | 44% males, 14–73 y | 3 pregnant women | 5 ganciclovir, 1 acyclovir, 2 vidarabine, 19 none | 1/5 of those who received ganciclovir died, 13/22 of the remaining died |
| [8]/1985 | 62 | Myocarditis (10), pneumonia (8), encephalitis (7), gastrointestinal infection (8), granulomatous hepatitis (7), haemolytic anaemia (5), icteric hepatitis (3), conjunctivitis (3) severe thrombocytopenia (2), pericarditis (2), meningitis (2), VIII cranial nerve palsy (1), uveitis (1), chorioretinitis (1), rash (2) | ND for the majority 39.8 years old (for patients with granulomatous hepatitis, uveitis, chorioretinitis, gastrointestinal) | ND | ND | All survived except for 3 who died (1 with pericarditis and 2 with gastrointestinal infection) Relapses in one patient with uveitis and persistence in 1 with chorioretinitis |
Abbreviations PVT: portal vein thrombosis, MA: mean age, y: years, m: months, NM: non immune-modulating conditions, NC: no comorbidities, MR: mortality rate, SR: spontaneous remission rate, IBD: inflammatory bowel disease, APA: antiphospholipid antibodies, FVLH: factor V Leiden heterozygous mutation, ND: no data, AT: antiviral treatment, CR: complete recovery, PR: partial recovery, CMV: cytomegalovirus.
**: patients with more severe infections were administered AT.
#:Total number of reports by Karakozis is 38. However 23 patients reviewed by Karakozis and Galiatsatos are the same, and thus deducted from the Karakozis study.